Investigating the role of HTRA1 in causing kidney disease
The Serine Protease HTRA1 Antigen: A Gateway to Elucidating Membranous Nephropathy Pathogenesis and the Targeting of Antigen Epitopes
['FUNDING_OTHER'] · UNIVERSITY OF UTAH · NIH-11075806
This study is looking at how certain antibodies in people with primary membranous nephropathy (a kidney condition) affect the disease and aims to find better ways to diagnose and treat it, using new animal models to learn more about how the disease works.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF UTAH (nih funded) |
| Locations | 1 site (SALT LAKE CITY, UNITED STATES) |
| Trial ID | NIH-11075806 on ClinicalTrials.gov |
What this research studies
This research focuses on primary membranous nephropathy (MN), an autoimmune condition that leads to kidney damage. It aims to understand how autoantibodies against the serine protease HTRA1 contribute to the disease's progression. By identifying specific HTRA1 epitopes targeted by these autoantibodies, the research seeks to improve diagnosis and treatment outcomes for patients with MN. The study will utilize newly developed animal models to explore the mechanisms of disease development and the role of HTRA1 in kidney function.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with primary membranous nephropathy or those exhibiting symptoms of nephrotic syndrome.
Not a fit: Patients with kidney diseases unrelated to autoimmune mechanisms or those without membranous nephropathy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better diagnostic tools and targeted therapies for patients suffering from membranous nephropathy.
How similar studies have performed: Previous research has shown promise in understanding autoimmune mechanisms in kidney diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
SALT LAKE CITY, UNITED STATES
- UNIVERSITY OF UTAH — SALT LAKE CITY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: AL-RABADI, LAITH — UNIVERSITY OF UTAH
- Study coordinator: AL-RABADI, LAITH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.